JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed. It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55.



Investigated for use/treatment in macular degeneration.


The integrin α5β1 is expressed on several types of inflammatory cells and mediates the migration of these cells into the inflamed tissue. By administering JSM-6427, the infiltration of inflammatory cells into the inflamed tissue will be inhibited and thus inflammation suppressed as shown in models o... Read more

Mechanism of action

Wet AMD causes vision loss due to abnormal growth of new blood vessels in the choriocapillaris. New blood vessels arise as a result of proliferation, migration and differentiation of pre-existing blood vessel cells (endothelium). In order for the endothelium to form functional new blood vessels, the... Read more


Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.


Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.


Information currently not available.

Adverse Effects


Information currently not available.

Food Interactions

    Information currently not available.


Type in a drug name to check for interaction with JSM 6427
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
2 References
  1. 1 . Maier AK, Kociok N, Zahn G, Vossmeyer D, Stragies R, Muether PS, Joussen AM: Modulation of hypoxia-induced neovascularization by JSM6427, an integrin alpha5beta1 inhibiting molecule. Curr Eye Res. 2007 Sep;32(9):801-12.PubMed: 17882713
  2. 2 . Umeda N, Kachi S, Akiyama H, Zahn G, Vossmeyer D, Stragies R, Campochiaro PA: Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. Mol Pharmacol. 2006 Jun;69(6):1820-8. Epub 2006 Mar 9.PubMed: 16527907